ThePennyStockProfiler.com providing you the best fundamental coverage of VNDA, VVUS, AMGN and ARIA
New York, NY -- (SBWIRE) -- 12/19/2012 -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced a late stage experiment of drug which treats a rare disorder affecting blind people, it touched its main goal of showing improvement over a placebo, it turned its shares almost 37% up.
Company stated in a statement that it tested this drug for non-24-hour disorder a rare and chronic circadian rhythm disorder, the disease for which there is no approved treatment.
Vanda Pharmaceuticals stated that their late stage experiment of drughis drug is beneficial for blind people for their rare disease the main task to making for this drug of screening the development over a placebo. According to Vanda this drug is being tested for non 24 hour disorder this is very uncommon and dangerous circadian rhythm disorder and this disease had not any approved treatment.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at the price of $4.03 whereas its previous closing price was recorded at $3.83. VNDA gained 18.94% and traded within the day range of $3.76 - $4.42 for the day, 52 week range of the stock remained in between $2.92 - $5.47. Total volume of the stock was 4.70 million shares during last trade while its average volume is 159,660.00 shares.
Company’s total market capitalization stands at $108.11 billion along with 28.23 million outstanding shares.
What was the Moving Force behind VNDA On Bullish Run? Find Out Here
VIVUS, Inc. (NASDAQ:VVUS) percentage change jumped +0.50% to close at $13.14 with the total traded volume of 5.74 million shares more than average volume of 5.51 million shares.
Company’s lowest price during last trade was $12.85 while its highest price remained $13.47 for the day. VVUS’s total market capitalization is $1.32 billion along with 100.59 million shares outstanding. Its beta value stands at 1.17 points and its earning per shares remained $-0.98.
For How Long VVUS’s Gloss will Attract Investors? Just Go Here and Find Out
Amgen, Inc. (NASDAQ:AMGN) reported a plunge of -0.23% after opening at the price of $89.99 its closing price for the day was $89.29.
AMGN’s total trading volume for the day was 5.51 million shares versus its average volume of 4.02 million shares. Company’s current market capitalization stands at $68.52 billion along with 767.36 million shares.
Amgen Company’s earning per share is $5.59 while its beta value stands at 0.41 times.
Has AMGN Found The Bottom and Ready To Move Up? Find Out Here
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported the upsurge of 0.75% and closed at $20.18 with the total traded volume of 4.58 million shares, stock’s opening price was $20.20. The company has total of 166.66 million outstanding shares and its total market capitalization is $3.36 billion.
52-week price range of the stock remained $11.27 - $25.40, while during last trade its minimum price was $19.90 and it gained highest price of $20.28.
Will ARIA Continue To Move Higher? Find Out Here
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at www.ThePennyStockProfiler.com
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)